Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free VHI Stock Alerts

Vitalhub (VHI) Competitors

Vitalhub logo
C$7.90 -0.11 (-1.37%)
As of 04:00 PM Eastern
Compare

VHI vs. CARE, RHT, ADK, DOC, and ZMD

Should you buy Vitalhub stock or one of its competitors? Vitalhub's main competitors and comparable companies include Dialogue Health Technologies (CARE), Reliq Health Technologies (RHT), DIAGNOS (ADK), CloudMD Software & Services (DOC), and ZoomMed (ZMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Vitalhub compare to Dialogue Health Technologies?

Vitalhub (TSE:VHI) and Dialogue Health Technologies (TSE:CARE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Vitalhub had 3 more articles in the media than Dialogue Health Technologies. MarketBeat recorded 3 mentions for Vitalhub and 0 mentions for Dialogue Health Technologies. Vitalhub's average media sentiment score of 0.00 equaled Dialogue Health Technologies'average media sentiment score.

Company Overall Sentiment
Vitalhub Neutral
Dialogue Health Technologies Neutral

Vitalhub has a beta of 0.914183, indicating that its share price is 9% less volatile than the broader market. Comparatively, Dialogue Health Technologies has a beta of 2.66, indicating that its share price is 166% more volatile than the broader market.

Vitalhub has a net margin of 5.89% compared to Dialogue Health Technologies' net margin of -19.73%. Vitalhub's return on equity of 2.79% beat Dialogue Health Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Vitalhub5.89% 2.79% 3.81%
Dialogue Health Technologies -19.73%-19.76%-10.01%

25.6% of Vitalhub shares are owned by institutional investors. Comparatively, 47.0% of Dialogue Health Technologies shares are owned by institutional investors. 18.6% of Vitalhub shares are owned by company insiders. Comparatively, 11.7% of Dialogue Health Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vitalhub currently has a consensus target price of C$12.67, indicating a potential upside of 60.34%. Given Vitalhub's stronger consensus rating and higher possible upside, equities analysts plainly believe Vitalhub is more favorable than Dialogue Health Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Dialogue Health Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Vitalhub has higher revenue and earnings than Dialogue Health Technologies. Dialogue Health Technologies is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VitalhubC$127.08M3.93C$3.35MC$0.1265.83
Dialogue Health TechnologiesC$95.88M0.00-C$19.50M-C$0.30N/A

Summary

Vitalhub beats Dialogue Health Technologies on 13 of the 15 factors compared between the two stocks.

How does Vitalhub compare to Reliq Health Technologies?

Vitalhub (TSE:VHI) and Reliq Health Technologies (CVE:RHT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Vitalhub has a net margin of 5.89% compared to Reliq Health Technologies' net margin of -95.54%. Vitalhub's return on equity of 2.79% beat Reliq Health Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Vitalhub5.89% 2.79% 3.81%
Reliq Health Technologies -95.54%-221.64%-5.30%

Vitalhub has higher revenue and earnings than Reliq Health Technologies. Reliq Health Technologies is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VitalhubC$127.08M3.93C$3.35MC$0.1265.83
Reliq Health TechnologiesN/AN/AN/A-C$0.02N/A

Vitalhub has a beta of 0.914183, indicating that its share price is 9% less volatile than the broader market. Comparatively, Reliq Health Technologies has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

Vitalhub currently has a consensus target price of C$12.67, indicating a potential upside of 60.34%. Given Vitalhub's stronger consensus rating and higher possible upside, analysts plainly believe Vitalhub is more favorable than Reliq Health Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Reliq Health Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

25.6% of Vitalhub shares are owned by institutional investors. Comparatively, 2.8% of Reliq Health Technologies shares are owned by institutional investors. 18.6% of Vitalhub shares are owned by insiders. Comparatively, 1.8% of Reliq Health Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Vitalhub had 3 more articles in the media than Reliq Health Technologies. MarketBeat recorded 3 mentions for Vitalhub and 0 mentions for Reliq Health Technologies. Vitalhub's average media sentiment score of 0.00 equaled Reliq Health Technologies'average media sentiment score.

Company Overall Sentiment
Vitalhub Neutral
Reliq Health Technologies Neutral

Summary

Vitalhub beats Reliq Health Technologies on 13 of the 14 factors compared between the two stocks.

How does Vitalhub compare to DIAGNOS?

DIAGNOS (CVE:ADK) and Vitalhub (TSE:VHI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Vitalhub has a net margin of 5.89% compared to DIAGNOS's net margin of -6,956.84%. DIAGNOS's return on equity of 11,659.44% beat Vitalhub's return on equity.

Company Net Margins Return on Equity Return on Assets
DIAGNOS-6,956.84% 11,659.44% -134.33%
Vitalhub 5.89%2.79%3.81%

DIAGNOS has a beta of -0.141396, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Vitalhub has a beta of 0.914183, indicating that its stock price is 9% less volatile than the broader market.

Vitalhub has a consensus target price of C$12.67, indicating a potential upside of 60.34%. Given Vitalhub's stronger consensus rating and higher probable upside, analysts plainly believe Vitalhub is more favorable than DIAGNOS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DIAGNOS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

0.3% of DIAGNOS shares are owned by institutional investors. Comparatively, 25.6% of Vitalhub shares are owned by institutional investors. 16.8% of DIAGNOS shares are owned by company insiders. Comparatively, 18.6% of Vitalhub shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vitalhub has higher revenue and earnings than DIAGNOS. DIAGNOS is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DIAGNOSC$65.48K689.62-C$3.81M-C$0.04N/A
VitalhubC$127.08M3.93C$3.35MC$0.1265.83

In the previous week, Vitalhub had 3 more articles in the media than DIAGNOS. MarketBeat recorded 3 mentions for Vitalhub and 0 mentions for DIAGNOS. DIAGNOS's average media sentiment score of 0.00 equaled Vitalhub'saverage media sentiment score.

Company Overall Sentiment
DIAGNOS Neutral
Vitalhub Neutral

Summary

Vitalhub beats DIAGNOS on 14 of the 16 factors compared between the two stocks.

How does Vitalhub compare to CloudMD Software & Services?

CloudMD Software & Services (CVE:DOC) and Vitalhub (TSE:VHI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

CloudMD Software & Services has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Vitalhub has a beta of 0.914183, indicating that its share price is 9% less volatile than the broader market.

Vitalhub has higher revenue and earnings than CloudMD Software & Services. CloudMD Software & Services is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CloudMD Software & ServicesC$90.91M0.12-C$76.56M-C$0.23N/A
VitalhubC$127.08M3.93C$3.35MC$0.1265.83

Vitalhub has a net margin of 5.89% compared to CloudMD Software & Services' net margin of -91.12%. Vitalhub's return on equity of 2.79% beat CloudMD Software & Services' return on equity.

Company Net Margins Return on Equity Return on Assets
CloudMD Software & Services-91.12% -102.91% -8.74%
Vitalhub 5.89%2.79%3.81%

0.5% of CloudMD Software & Services shares are owned by institutional investors. Comparatively, 25.6% of Vitalhub shares are owned by institutional investors. 0.1% of CloudMD Software & Services shares are owned by insiders. Comparatively, 18.6% of Vitalhub shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vitalhub has a consensus price target of C$12.67, indicating a potential upside of 60.34%. Given Vitalhub's stronger consensus rating and higher possible upside, analysts plainly believe Vitalhub is more favorable than CloudMD Software & Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CloudMD Software & Services
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

In the previous week, Vitalhub had 3 more articles in the media than CloudMD Software & Services. MarketBeat recorded 3 mentions for Vitalhub and 0 mentions for CloudMD Software & Services. CloudMD Software & Services' average media sentiment score of 0.00 equaled Vitalhub'saverage media sentiment score.

Company Overall Sentiment
CloudMD Software & Services Neutral
Vitalhub Neutral

Summary

Vitalhub beats CloudMD Software & Services on 15 of the 16 factors compared between the two stocks.

How does Vitalhub compare to ZoomMed?

ZoomMed (CVE:ZMD) and Vitalhub (TSE:VHI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Vitalhub has a consensus target price of C$12.67, indicating a potential upside of 60.34%. Given Vitalhub's stronger consensus rating and higher probable upside, analysts clearly believe Vitalhub is more favorable than ZoomMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZoomMed
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

Vitalhub has higher revenue and earnings than ZoomMed. ZoomMed is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZoomMedC$10K203.39-C$1.49M-C$0.01N/A
VitalhubC$127.08M3.93C$3.35MC$0.1265.83

Vitalhub has a net margin of 5.89% compared to ZoomMed's net margin of 0.00%. Vitalhub's return on equity of 2.79% beat ZoomMed's return on equity.

Company Net Margins Return on Equity Return on Assets
ZoomMedN/A N/A N/A
Vitalhub 5.89%2.79%3.81%

25.6% of Vitalhub shares are held by institutional investors. 18.6% of Vitalhub shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vitalhub had 3 more articles in the media than ZoomMed. MarketBeat recorded 3 mentions for Vitalhub and 0 mentions for ZoomMed. ZoomMed's average media sentiment score of 0.00 equaled Vitalhub'saverage media sentiment score.

Company Overall Sentiment
ZoomMed Neutral
Vitalhub Neutral

Summary

Vitalhub beats ZoomMed on 14 of the 15 factors compared between the two stocks.

Get Vitalhub News Delivered to You Automatically

Sign up to receive the latest news and ratings for VHI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VHI vs. The Competition

Export
MetricVitalhubHealthcare Technology IndustryHealthcare SectorTSE Exchange
Market CapC$499.75MC$1.62BC$7.06BC$12.54B
Dividend YieldN/A4.69%2.57%6.20%
P/E Ratio65.8324.17269.0630.69
Price / Sales3.9372.88602.439.75
Price / CashN/A30.7570.4882.29
Price / Book1.826.5212.914.60
Net IncomeC$3.35M-C$25.90MC$3.45BC$299.09M
7 Day Performance0.13%3.06%1.12%0.94%
1 Month Performance8.37%5.27%1.79%3.90%
1 Year Performance-37.94%-15.58%67.69%36.05%

Vitalhub Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VHI
Vitalhub
2.1137 of 5 stars		C$7.90
-1.4%		C$12.67
+60.3%		-39.9%C$499.75MC$127.08M65.832,250
CARE
Dialogue Health Technologies
N/AN/AN/AN/AC$345.36MC$95.88MN/A730
RHT
Reliq Health Technologies
N/AC$0.22
flat		N/A+0.0%C$46.65MN/AN/A12,600
ADK
DIAGNOS
N/AC$0.30
+9.1%		N/A+42.9%C$36.12MC$65.48KN/AN/A
DOC
CloudMD Software & Services
N/AC$0.04
flat		N/A+0.0%C$10.66MC$90.91MN/A200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:VHI) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel